Visão geral da empresa
A biopharmaceutical enterprise, Supernus Pharmaceuticals, Inc. is primarily engaged in the development and commercialization of therapeutic products designed for the treatment of central nervous system diseases within the United States market. The company operates within the broader healthcare sector, specifically specializing in the drug manufacturing industry for both specialty and generic formulations, a classification that typically involves high research and development expenditures and targeted therapeutic areas. At present, the organization employs approximately 778 individuals to support its operations and product lifecycle management. The company holds a market capitalization of $2.97 billion and generated annual revenue of $718.95 million in the trailing twelve months. These valuation and revenue figures indicate that Supernus maintains a mid-cap position in the pharmaceutical landscape, suggesting a scale capable of sustaining significant R&D initiatives while still facing the typical volatility associated with biotechnology and specialty drug development sectors.
Saúde financeira
In the trailing twelve months, the company reported total revenue of $718.95 million, while recording a net income loss of $38.55 million and an EBITDA of $44.40 million. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, likely including significant R&D and commercialization costs, are currently outpacing profitability, resulting in a loss before interest and taxes are considered. Despite the accounting losses, the company generated positive free cash flow of $55.72 million, which provides a critical buffer for financial flexibility, allowing management to fund operations, invest in pipeline assets, or manage capital allocation without immediate reliance on external equity financing. Profitability analysis shows a gross margin of 89.6%, indicating highly efficient production costs typical of pharmaceutical manufacturing, but this is contrasted by an operating margin of -28.9% and a profit margin of -5.4%, reflecting the heavy burden of operating expenses on overall earnings. The balance sheet presents a conservative profile with cash holdings of $308.67 million significantly exceeding total debt obligations of $40.98 million, a disparity further highlighted by a debt-to-equity ratio of 3.86 which, while numerically high, must be viewed in the context of strong cash liquidity. Short-term liquidity is robust, evidenced by a current ratio of 1.91, which suggests the company holds sufficient current assets to cover its current liabilities with more than double the necessary margin. However, return metrics show a return on equity of -3.7% and a return on assets of -2.1%, indicating that management has not yet generated positive returns on the capital base due to the current stage of business development and the time required to translate R&D investments into profitable product sales.
Avaliação de valorização
Valuation multiples present a complex picture, with a trailing P/E ratio of N/A due to the absence of net income in the trailing twelve months, while the forward P/E stands at 12.23, implying market expectations for future earnings recovery. The forward P/E of 12.23 is notably lower than the price-to-book ratio of 2.79, suggesting the market prices future earnings potential at a discount relative to the company's tangible book value. Additionally, the price-to-sales ratio of 4.13 and an EV/EBITDA of 60.91 indicate that the stock is priced on a significant premium relative to sales and EBITDA, reflecting investor confidence in the proprietary nature of its CNS disease treatments and future revenue streams. The stock's price has fluctuated within a 52-week range between a low of $29.16 and a high of $59.68, placing the current trading value in a position that requires calculation relative to these extremes to determine the percentage distance from recent highs or lows. The beta of 0.73 indicates that the stock's price volatility is historically lower than the broader market, suggesting it may serve as a defensive holding within a portfolio of healthcare stocks despite the inherent risks of the biopharmaceutical sector.
Growth & Income
The company demonstrated revenue growth of 21.5% year-over-year, whereas earnings growth is listed as N/A, indicating that revenue expansion is currently outpacing profitability rather than the other way around. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all earnings are retained and reinvested directly into growth initiatives such as clinical trials and product commercialization rather than distributed to shareholders. The absence of a dividend payout ratio highlights a strategy prioritizing capital allocation toward the development pipeline over immediate income generation for investors. Consequently, the overall growth and income profile characterizes Supernus as a capital-intensive growth company that relies on future earnings realization to support shareholder value rather than providing current income through dividends.